(231 days)
No
The device description and performance studies focus on the physical characteristics and mechanical performance of a catheter and stylet for delivering local anesthetic. There is no mention of any computational or data-driven components.
Yes
The device is used to deliver local anesthetic, which is a therapeutic intervention for pain relief.
No
The device description clearly states its purpose is "Assistance in the delivery of local anaesthetic," which is a treatment or therapy, not a diagnostic act. It functions to administer a substance, not to identify or assess a medical condition.
No
The device description clearly details a physical catheter and stylet, which are hardware components. The performance studies also focus on the physical properties and performance of these hardware components.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is "Assistance in the delivery of local anaesthetic after hamstring ligament reconstruction procedures." This describes a device used in vivo (within the body) for delivering medication.
- Device Description: The description details a catheter and stylet designed for insertion into a surgical site to deliver anesthetic. This is a medical device used for a therapeutic or procedural purpose, not for testing samples in vitro.
- Lack of IVD Characteristics: There is no mention of the device being used to examine specimens (blood, urine, tissue, etc.) outside of the body to provide information about a physiological state, health, or disease.
IVD devices are specifically designed for testing samples in vitro to diagnose, monitor, or screen for conditions. This device's function is entirely focused on delivering medication directly into a surgical site within the patient's body.
N/A
Intended Use / Indications for Use
Assistance in the delivery of local anaesthetic after hamstring ligament reconstruction procedures
Product codes
BSP
Device Description
GRAFTSITE is 28.25 cm in length with an inner diameter of 2.6 mm and an outer diameter of 4.0 mm, sized to fit down the hamstring harvest site. It is rounded and blocked at the patient end and has a 6% female luer at the user end. There are lateral eyes over a length at the patient end of the catheter. A buttoned stylet consisting of a rigid stainless steel rod of diameter slightly less than the bore of the catheter, functions to stiffen the device. GRAFTSITE can be used to directly administer a bolus of the users chosen local anesthetic, via injection down the lumen of the catheter, into the terminus of the gutter at the site of comorbidity.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
hamstring harvest site / femoral gutter
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-clinical testing: Based on the characteristics identified as relevant from performance standards, GRAFTSITE was directly compared to the predicate in comparative performance tests. Testing performed in order to verify substantial equivalence included:
- Pressure testing of the catheter/hub for resistance to liquid leakage (in accordance with EN 1618 and ISO 594-2)
- Tensile bond performance of the catheter/hub and stylet/button (in accordance with BS 6196 and EN 1618)
- Corrosion resistance of the stylet (as per EN 1618)
- Flow rate of the catheter (in accordance with EN 1618)
- Radio-opacity of the catheter (in accordance with ASTM F640-12)
- Human factors/usability validation of the device
GRAFTSITE performed equally well in all performed tests necessary to demonstrate that it is substantially equivalent to the predicate.
Biocompatibility testing on the fully finished device demonstrated that GRAFTSITE is biocompatible in relation to its intended use in accordance with ISO 10993-1 and the FDA guidance document on that standard. This test process included cytotoxicity, sensitization, irritation/intracutaneous reactivity, acute systemic toxicity, material-mediated pyrogenicity, particulate analysis, hemolysis, and endotoxin testing.
Gamma irradiation validation using the VDmax25 method, in accordance with ISO 11137-1 and ISO 11137-2, was successful in eliciting no growth for a routine processing dose of 25-40kGy and giving a SAL of 10-6 (in accordance with EN 556).
Clinical testing: Clinical data was not required to establish substantial equivalence between GRAFTSITE and the predicate device.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 868.5150 Anesthesia conduction needle.
(a)
Identification. An anesthesia conduction needle is a device used to inject local anesthetics into a patient to provide regional anesthesia.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
May 18, 2018
Summit Medical Ltd. Robyn Cochrane RA Executive - Projects Industrial Park Bourton on the Water Gloucestershire GL54 2HO United Kingdom
Re: K173110
Trade/Device Name: Graftsite Local Anesthetic Delivery Assistance Device Regulation Number: 21 CFR 868.5150 Regulation Name: Anesthesia Conduction Needle Regulatory Class: Class II Product Code: BSP Dated: April 2, 2018 Received: April 2, 2018
Dear Robyn Cochrane:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part
1
801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Michael J. Ryan -S
for Tina Kiang, Ph.D. Acting Director Division of Anesthesiology, General Hospital, Respiratory, Infection Control, and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
510(k) Number (if known) K173110
Device Name
GRAFTSITE Local Anesthetic Delivery Assistance Device
Indications for Use (Describe) Assistance in the delivery of local anaesthetic after hamstring ligament reconstruction procedures
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
_ Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Druq Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary – K173110 Summit Medical Ltd GRAFTSITE
Summit Medical Ltd.
Part of the OrthoD Group
Head Office Industrial Park Bourton-on-the-Water GL54 2HQ United Kingdom
tel: +44 (0) 1451 821 311 email: info@orthod.com website: www.orthod.com
| Date prepared | 17/May/2018 |
|---|---|
| Submitter | Summit Medical Ltd |
| Contact person | Robyn Cochrane |
| Project Manager | |
| Summit Medical | |
| Industrial Park | |
| Bourton-on-the-Water | |
| Gloucestershire | |
| GL54 2HQ | |
| Phone: + 44(0)1451 823357 | |
| Fax: +44 (0)1451 821092 | |
| Email: robyn.cochrane@orthod.com | |
| Name of device | GRAFTSITE Local Anesthetic Delivery Assistance Device |
| Classification | Classification - II |
| Product Code - BSP | |
| Classification name – Anesthesia conduction needle | |
| Classification Rule - 868.5150 | |
| Device Panel – 73 - “Anesthesiology” | |
| Predicate device(s) | Pajunk® “Unipolar Needles”, initially cleared under K000722 and |
| subsequently cleared under part of Special 510(k) K053283 | |
| (under new trade name UniPlex NanoLine cannula). | |
| Indications for use | GRAFTSITE Indications for Use Statement - "Assistance in the |
| delivery of local anaesthetic after hamstring harvest during | |
| ligament reconstruction procedures." |
The Indications for Use statement of GRAFTSITE is different to
that of the predicate device - "The PAJUNK needles are used to
puncture the tissue in order to gain entry and locally inject
anesthetics to induce regional anesthesia. An electrical stimulus
may be applied to the needle via a cable and connector to assist
the physician pinpoint the area of application." due to
GRAFTSITE having a more limited depiction of use compared to
that of the predicate.
GRAFTSITE has a catheter round and blocked at the patient end
as is not required to puncture tissue to gain entry, due to the |
| | |
| | method of access being through the already present femoral
gutter, compared to the predicate that requires a puncturing tip
at the end of the cannula in order to pierce the skin for nerve
access. Therefore, this difference does not raise different
questions of safety and effectiveness. |
| | GRAFTSITE is used for inducing regional anesthesia by
assisting in the injection of anesthetics like the predicate, it just
has a more limited depiction of use to only after hamstring
harvest during ligament reconstruction procedures. In
subsequent clearance K053283 it states that PAJUNK Unipolar
needles (initially cleared under K000722) are marketed as single
shot needles under the trade name UniPlex and that the
anesthesia conduction catheter allows for bolus injections or
continuous infusion of local anesthetics. This shows the
predicate can be used for the same intended purpose as
GRAFTSITE, assisting in delivery of a bolus of anesthetic,
therefore this does not raise different questions of safety or
effectiveness. |
| | GRAFTSITE does not require the physician to pinpoint the area
of application via electrical stimulus, as it fulfils its intended use
through localization of anesthetic directly to nerve endings
within, and surrounding, the comorbidities at the already femoral
gutter, compared to the predicate which utilizes nerve stimulation
to localize the more proximal nerve sheath. Therefore, this
difference does not raise different questions of safety and
effectiveness. |
| Device description | GRAFTSITE is 28.25 cm in length with an inner diameter of 2.6
mm and an outer diameter of 4.0 mm, sized to fit down the
hamstring harvest site. It is rounded and blocked at the patient
end and has a 6% female luer at the user end. There are lateral
eyes over a length at the patient end of the catheter. A buttoned
stylet consisting of a rigid stainless steel rod of diameter slightly
less than the bore of the catheter, functions to stiffen the device.
GRAFTSITE can be used to directly administer a bolus of the
users chosen local anesthetic, via injection down the lumen of
the catheter, into the terminus of the gutter at the site of
comorbidity. |
| Non-clinical testing | Based on the characteristics identified as relevant from
performance standards, GRAFTSITE was directly compared to
the predicate in comparative performance tests. |
| | Testing performed in order to verify substantial equivalence
included: |
4
5
Pressure testing of the catheter/hub for resistance to ● liquid leakage (in accordance with EN 1618 and ISO 594-2) Tensile bond performance of the catheter/hub and . stylet/button (in accordance with BS 6196 and EN 1618) Corrosion resistance of the stylet (as per EN 1618) ● . Flow rate of the catheter (in accordance with EN 1618) Radio-opacity of the catheter (in accordance with ASTM ● F640-12) Human factors/usability validation of the device ● GRAFTSITE performed equally well in all performed tests necessary to demonstrate that it is substantially equivalent to the predicate. The catheter luer hub is manufactured in accordance with EN1707/ISO 594-2 and BS EN 20594-1/ISO 594-1. Further testing specific to ISO 594-1/ISO 594-2 was not required due to the following; Gauging testing - no axial force applied during intended ● use . Air leakage during aspiration - no aspiration during intended use . Separation force - no axial force applied during intended use . Stress cracking - limited stress applied during intended duration of use (≤1 minute) Unscrewing torque - no unscrewing torque applied during . intended use Ease of assembly - no axial or rotational force applied . during intended use . Resistance to overriding - no torque applied during intended use In addition, the requirement for a compliant 6% luer syringe, in accordance with ISO 594-2, to be used in conjunction with the device is indicated to users in the IFU. Biocompatibility testing on the fully finished device demonstrated that GRAFTSITE is biocompatible in relation to its intended use in accordance with ISO 10993-1 and the FDA guidance document on that standard, and is therefore determined to be
6
| | biocompatible within a risk management process. This test
process included cytotoxicity, sensitization, irritation/
intracutaneous reactivity, acute systemic toxicity, material-
mediated pyrogenicity, particulate analysis, hemolysis, and
endotoxin testing. |
|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | Gamma irradiation validation using the VDmax25 method, in
accordance with ISO 11137-1 and ISO 11137-2, was successful
in eliciting no growth for a routine processing dose of 25-40kGy
and giving a SAL of 10-6 (in accordance with EN 556). |
| Clinical testing | Clinical data was not required to establish substantial
equivalence between GRAFTSITE and the predicate device. |
| Physical differences | Both GRAFTSITE and the predicate are constructed of
established, clinically used materials, with confirmatory
biocompatibility testing verifying this. |
| | The catheter being rounded and blocked at the patient end is
due to the method of access being through the already present
femoral gutter, compared to the predicate that requires a
puncturing tip at the end of the cannula in order to pierce the
skin to access the femoral nerve. |
| | The length of the catheter is significantly longer due to the
requirement for placement at the terminus of the proximal
femoral gutter compared to the predicate, which typically only
requires access 2 – 3cm below the skin. |
| | The stainless steel stylet assembly of GRAFTSITE provides
rigidity to the catheter upon insertion compared to the predicate
which has a rigid stainless steel cannula for insertion |
| | The presence of a stimulator cable with the predicate is due to
the indications for use (i.e. for the localization of peripheral nerve
bundles through nerve stimulation). GRAFTSITE is not indicated
for peripheral nerve stimulation. |
| | Comparative in vitro testing was performed, with the results for
GRAFTSITE compared to the predicate, which showed that
there were no different questions of safety and effectiveness
raised. |
| Handling
differences | Whilst the predicate is of a clinically standard technique,
GRAFTSITE was proven to be usable in a cadaveric usability
investigation, and did not raise different questions of safety and
effectiveness when compared to the predicate |
| Chemical
differences | Both GRAFTSITE and the predicate are constructed of
established, clinically used materials, with confirmatory
biocompatibility testing verifying this. Comparative in vitro testing
was performed, with the results for GRAFTSITE compared to the
predicate. |
| Substantial
equivalence | Based on the similarities in design, function, indications for use
and fundamental scientific technology, the subject devices of this
submission is similar to the predicate device and does not raise
different questions of safety and effectiveness. Therefore,
Summit Medical concludes that the subject device, GRAFTSITE,
is substantially equivalent to the predicate device. |
7